Bodyline is a low dose naltrexone treatment clinical specialist with the potential to treat diverse conditions including Crohn’s disease, chronic pain, fibromyalgia, psoriasis and long covid. It also has the additional benefits to prescribe LDN to support weight loss, improve general wellbeing, reduce cravings, and support women’s health. 

If you have been treated in the past with more conventional medications for your illness and you are still suffering, then LDN could be an option for you. LDN is a safe, non-toxic, and effective medication that helps to regulate a dysfunctional immune system and reduces pain and fights inflammation. 

The exact mechanism of action of LDN by modulating the body’s immune response and affecting to production of endorphins. LDN works by “tricking” the brain into producing more natural opioids (these are called endogenous opioids). It does this by binding briefly to opioid receptors, blocking our naturally occurring opioids from binding. Our body counteracts this by producing more naturally occurring opioids to “wash off” the low dose naltrexone. This increases the levels of naturally occurring opioids in our body which makes us feel good and provides pain relief.

Low dose naltrexone has a very short half-life – around 4 to 6 hours – which means its binding effects wear off quickly, but this is long enough to boost levels of naturally occurring opioids for 18 to 24 hours. Endogenous opioids are natural pain relievers and having more of these around in the body is one of the ways low dose naltrexone is thought to work.

Low dose naltrexone also appears to have anti-inflammatory effects by regulating microglial cells which have a key role in general and nerve inflammation. When microglial cells are activated, they produce pro-inflammatory cytokines, free radicals (reactive oxygen species), and nitric oxide – all of these substances have been associated with pain, inflammation, fatigue, feeling rundown or like you have come down with something. Low dose naltrexone is also thought to stop microglial cells from being activated by blocking the TLR-4 receptor.